International Immunopharmacology, Journal Year: 2024, Volume and Issue: 131, P. 111829 - 111829
Published: March 14, 2024
Language: Английский
COVID, Journal Year: 2025, Volume and Issue: 5(4), P. 44 - 44
Published: March 22, 2025
The emergence of COVID-19 necessitated the rapid development vaccines. While highly effective at reducing severe disease and death, breakthrough infections remain a problem as virus continues to mutate. To help address this issue, we show utility multiplex immunoassay in measuring multiple aspects antibody response generated by SARS-CoV-2 We use platform measure spike-specific IgG concentration, avidity, receptor-binding inhibition. In addition, correlate results from an ACE-2 inhibition assay with corresponding data microneutralization establish inhibitory potential predictor neutralization. studied these responses SARS-CoV-2-naïve -convalescent vaccinees. Our showed increased concentrations, following vaccination both groups. were also able differentiate immune between two groups using look diversity. has strong correlations cell-based pseudovirus neutralization well WT Washington Delta variant PRNT50 assays. This suggests that may be simultaneously predict different variants. Overall, developed custom several experimental variations is powerful tool assessing vaccinated individuals.
Language: Английский
Citations
0
BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 7, 2025
Abstract Background New vaccines with broader protection against SARS-CoV-2 are needed to reduce the risk of immune escape and provide broad long-lasting cellular immunity. The objectives naNO-COVID trial were evaluate safety immunogenicity a CD8 + T cell, gold nanoparticle-based, peptide COVID-19 vaccine. Methods A randomized, double-blind, vehicle-controlled, phase 1 in healthy adults receive PepGNP-Covid19 or Vehicle-GNP, followed over 180 days, using dose-escalation strategy. Results Twenty participants received (low dose [LD] high [HD], n = 10 each) six Vehicle-GNP (LD HD, 3 each). Vaccinations safe. No serious adverse events reported. Most mild, two special interest related product (fever fatigue). Reactogenicity was similar overall between vaccine, comparator, doses. Virus-specific humoral responses LD groups coincided infections. vaccination induced modulation Covid19-specific CD137 CD69 , an increase at day 35 particularly central effector memory cells group, late HD group. Conclusions favourable profile observed support further development PepGNP-Covid19. Trial registration ClinicalTrials.gov, NCT05113862, approved 09.11.2021.
Language: Английский
Citations
0
Vaccines, Journal Year: 2023, Volume and Issue: 11(7), P. 1186 - 1186
Published: June 30, 2023
(1) Background: SARS-CoV-2 T cell immunity is rapidly activated following infection and vaccination crucial for controlling progression severity. The aim of the present study was to compare levels responses between cohorts subjects with hybrid (convalescent vaccinated), vaccinated naïve (non-exposed) convalescent unvaccinated subjects. (2) Methods: We performed a retrospective descriptive analysis data collected from medical records adult individuals who were consecutively examined at large, private Medical Center Attica September 2021 2022 in order be on their own initiative response. They divided into three groups: Group A: subjects; B: C: response estimated against spike (S) nucleocapsid (N) structural proteins by performing methodology T-SPOT.COVID test. (3) Results: A total 530 retrospectively included study, 252 females (47.5%) 278 (52.5%) males ranging 13 92 years old (mean 55.68 ± 17.0 years). Among them, 66 (12.5%) A, 284 (53.6%) B 180 (34.0%) C. groups, reaction S antigen reported 58/66 (87.8%) 175/284 (61.6%) 146/180 (81.1%) C (chi-square, p < 0.001). Reaction N 49/66 (74.2%) 140/180 (77.7%) = 0.841). median SFC count 24 (range 0-218) 12 0-275) 18 0-160) (Kruskal-Wallis test, 0.001; pairwise comparisons: groups A-B, A-C, 0.147; B-C, SFCs 0-82) 0-168) 0.27 A-C groups). (4) Conclusions: Our findings suggest that natural cellular immunity, either alone or combined vaccination, confers stronger more durable protection compared vaccine-induced immunity.
Language: Английский
Citations
10
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Feb. 22, 2024
SARS-CoV-2 vaccination in rheumatoid arthritis (RA) patients treated with B cell-depleting drugs induced limited seroconversion but robust cellular response. We aimed to document specific T and cell immunity response vaccine booster doses breakthrough infection (BTI). included 76 RA rituximab who received up four or three plus BTI, addition vaccinated healthy donors (HD) control tumor necrosis factor inhibitor (TNFi). quantified anti-SARS-CoV-2 receptor-binding domain (RBD) Spike IgG, anti-nucleocapsid (NC) 92 circulating inflammatory proteins, Spike-binding cells, Spike-specific cells along comprehensive high-dimensional phenotyping functional assays. The time since the last infusion, persistent inflammation, age were associated RBD IgG seroconversion. vaccine-elicited serological was accompanied by an incomplete induction of peripheral memory occurred independently responses. Vaccine- BTI-elicited similar between HD ex vivo terms frequency phenotype cytotoxic vitro functionality differentiation profile cells. can induce effector T-cell responses that are reactivated BTI. Paused medication allowed after a dose (D4), especially lower enabling efficient humoral contributed overall development potential durable immunity.
Language: Английский
Citations
3
International Immunopharmacology, Journal Year: 2024, Volume and Issue: 131, P. 111829 - 111829
Published: March 14, 2024
Language: Английский
Citations
3